Invasive Pneumococcal Disease among Immunocompromised Persons: Implications for Vaccination Programs

Clinical Infectious Diseases

Volumn 62, Issue 2, 2016, Pages 139-147

  Shigayeva, Altynay ^a   Rudnick, Wallis ^a,b   Green, Karen ^a   Chen, Danny K ^c,d   Demczuk, Walter ^e   Gold, Wayne L ^b,f   Johnstone, Jennie ^g   Kitai, Ian ^b,h   Krajden, Sigmund ^b,g   Lovinsky, Reena ⁱ   Muller, Matthew ^b,j   Powis, Jeff ^k   Rau, Neil ^b,l   Walmsley, Sharon ^b,f   Tyrrell, Gregory ^m   Bitnun, Ari ^b,n   McGeer, Allison ^a,b   Almorhi, Huda ^o   Armstrong, Irene ^o   Yaffe, Barbara ^o   Baqi, Mahin ^o   Richardson, David ^o   Belhaj, Abdelbaset ^o   Matlow, Anne G ^o   Richardson, Susan ^o   Tran, Dat ^o   Deeks, Shelley ^o   Jamieson, Frances ^o   Devlin, Roslyn ^o   Matukas, Larissa ^o   De Villa, Eileen ^o   Dooling, Kathleen ^o   Dick, Hani ^o   Downey, James ^o   Farshait, Nataly ^o   Lee, King S ^o   Kapala, Julius ^o   Rebbapragada, Anu ^o   Katz, Kevin ^o   Loeb, Mark ^o   Smaill, Fiona ^o   Yamamura, Deborah ^o   Lovgren, Marguerite ^o   Rose, David ^o   Martin, Irene ^o   Opavsky, Anne ^o   O'Grady, Sharon ^o   Ostrowska, Krystyna ^o   Sarabia, Alicia ^o   Ma, Charlotte ^o   Plevneshi, Agron ^o   Pong Porter, Sylvia ^o   Willey, Barbara ^o   Wong, Kenny ^o   Rodgers, Jennifer ^o   Ricciuto, Daniel ^o   Silverman, Michael ^o   Sales, Valerie ^o   Shokry, Phoebe ^o   Simor, Andrew ^o   Vearncombe, Mary ^o   Wilson, Aurora ^o   more..

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Mackenzie Health   (Canada)

^d SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g ST JOSEPH S HEALTH CENTRE   (Canada)

^h Rouge Valley Health System   (Canada)

ⁱ SCARBOROUGH HOSPITAL   (Canada)

^j ST MICHAEL'S HOSPITAL   (Canada)

^k TORONTO EAST GENERAL HOSPITAL   (Canada)

^l Halton Healthcare Services   (Canada)

^m Provincial Public Health Laboratory   (Canada)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

^o NONE

more..

Author keywords

immunocompromised; IPD; pneumococcal vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPLENIA; BACTERIUM ISOLATE; BONE MARROW TRANSPLANTATION; CANADA; CHILD; CHRONIC KIDNEY FAILURE; CHRONIC LEUKEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPROMIZED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ORGAN TRANSPLANTATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; SICKLE CELL ANEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; CLASSIFICATION; COHORT ANALYSIS; FEMALE; HERD IMMUNITY; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNITY, HERD; IMMUNOCOMPROMISED HOST; INCIDENCE; INFANT; INFANT, NEWBORN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960126131     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ803     Document Type: Article

References (46)

1. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2012; 374:893-902.
2. Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: A systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8:e60273.
3. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9.
4. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, SPAT Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect 2010; 138:1804-10.
5. Kyaw M, Christie P, Clarke S, et al. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 2003; 37:1283-91.
6. Kumar D, Humar A, Plevneshi A, et al. IPD in solid organ transplant recipients-10-year prospective population surveillance. Am J Transplant 2007; 7:1209-14.
7. Klemets P, Lyytikainen O, Ruutu P, Ollgren J, Nuorti JP. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis 2008; 8:96.
8. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65:17-24.
9. National Advisory Committee on Immunization. Canadian Immunization Guide, 5th ed. Ottawa, Ontario: Minster of Public Works and Government Services Canada, 1998 (Cat. No. H40-8/1008E).
10. National Advisory Committee on Immunization (NACI). Vaccination of Specific populations. In: The Canadian Immunization Guide, part 4. Ottawa, Canada: The Public Health Agency of Canada (PHAC). Available at: http://www.phac-aspc.gc. ca/publicat/cig-gci/p04-pneu-eng.php#ru. Accessed 7 June 2015.
11. National Advisory Committee on Immunization (NACI). Statement on the use of conjugate pneumococcal vaccine: 13 valent in adults (Pneu-C-13). October 2013. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-5/index-eng.php. Accessed 7 June 2015.
12. Statistics Canada. Estimates of population by census division, sex and age group based on the Standard Geographical Classification (SGC) 2006, annual (persons). 2014. Available at: http://www5.statcan.gc.ca/cansim/. Accessed 7 June 2015.
13. RudnickW, Liu Z, Shigayeva A, et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine 2013; 31:5863-71.
14. Spellerberg B, Brandt C. Streptococcus. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, eds. Manual of clinical microbiology. 10th ed. Washington, DC: American Society for Microbiology Press, 2011:405-21.
15. Slotved H-C, Kaltoft M, Skovsted IC, Kerrn MB, Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol 2004; 42:2518-22.
16. Austrian R. The Quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976; 43:699-709.
17. Canadian Institute for Health Information (CIHI). Canadian Organ Replacement Register. Annual Report: Treatment of End-Stage Organ Failure in Canada, 2001 to 2010, Ottawa, Canada. 2011.
18. Broten L, Avina-Zubieta JA, Lacaille D, et al. Systemic autoimmune rheumatic disease prevalence in Canada: Updated analyses across 7 provinces. J Rheumatol 2014; 41:673-9.
19. FitzGerald JM, Haddon JM, Bradly-Kennedy C, Kuramoto L, Ford GT, RUSIC Study Group . Resource use study in COPD (RUSIC): A prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 2007; 14:145-52.
20. Lougheed MD, Garvey N, Chapman KR, et al. Variations and gaps in management of acute asthma in Ontario emergency departments. Chest 2009; 135:724-36.
21. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a populationbased cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013; 65:353-61.
22. Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting beta-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA 2014; 312:1114-21.
23. Zou GY, Donner A. Construction of confidence limits about effect measures: general approach. Stat Med 2008; 27:1693-702.
24. Lujan M, Burgos J, Gallego M, et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis 2013; 57:1722-30.
25. Harboe ZB, Larsen MV, Ladelund S, et al. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users. Clin Infect Dis 2014; 59:1168-76.
26. Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: The "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One 2014; 9:e87872.
27. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47:1012-20.
28. Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59:1066-73.
29. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-9.
30. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England andWales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15:535-43.
31. Rose MA, Christopoulou D, Myint TT, de Schutter I. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract 2014; 68:8-19.
32. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012; 66:1177-81.
33. Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1:ofu024.
34. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13:R139.
35. Brueggemann AB, Peto TE, Crook DW, Butler JC, Kristinsson KG, Spratt BG. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004; 190:1203-11.
36. Sjostrom K, Spindler C, Ortqvist A, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006; 42:451-9.
37. Imohl M, Reinert RR, Ocklenburg C, van der Linden M. Association of serotypes of Streptococcus pneumoniae with age in invasive pneumococcal disease. J Clin Microbiol 2010; 48:1291-6.
38. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49:e23-9.
39. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: A population-based cohort study 17. PLoS Med 2009; 6:e1000081.
40. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25.
41. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422.
42. Tsai YH, Hsieh MJ, Chang CJ, et al. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old-Taiwan's PPV vaccination program. Vaccine 2015; 33:2897-902.
43. Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: A retrospective case-control study. Clin Infect Dis 2015; 60:1472-80.
44. Ladhani SN, Andrews NJ,Waight P, Borrow R, Slack MP, Miller E. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales. Clin Infect Dis 2014; 58:517-25.
45. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, SPAT Group. Welders are at increased risk for invasive pneumococcal disease. Int J Infect Dis 2010; 14: e796-9.
46. Pelton SI, Shea KM, Weycker D, Farkouh RA, Strutton DR, Edelsberg J. Rethinking risk for pneumococcal disease in adults: The role of risk stacking. Open Forum Infect Dis 2015; 2:ofv020.